ArticleFrontiers in neurology2026
Diagnostic spectrum and clinical outcomes of chronic inflammatory demyelinating polyneuropathy: a multicenter cohort.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common immune-mediated demyelinating polyneuropathy, yet data from Arab populations are scarce. We present the first multicenter retrospective Arab cohort describing demographic, clinical, electrophysiological features, and treatment outcomes of CIDP. Methods: Electronic records from five hospitals in Saudi Arabia were searched between January 2014 and January 2025 for patients diagnosed with CIDP. Patients meeting 2021 EAN/PNS criteria, aged 3 to 80 years, with a minimum follow-up of 3 months were included. Outcome at initial and last visit assessed using MRCSS and INCAT disability scores, with minimal clinically important differences defined as a 4-point and 1-point change in each score, respectively. Results: Thirty-six (18 male, 18 female) met criteria (33 CIDP,3 possible CIDP). Onset age averaged 33 years (40 years in adult-onset cases). Typical CIDP was predominant (72%), with distal, motor-predominant, and multifocal variants representing 8% each. All motor demyelinating features were upper limb predominant. Maintenance monotherapy, mainly IVIG (42%) or oral steroids (33%), was used to treat 75% of patients. Over 55 months, meaningful improvement was achieved in 89% (INCAT) and 83% (MRCSS) with 3.7- and 11.9-point changes, respectively ( Conclusion: This is the first Arab multicenter CIDP study, which shows earlier disease onset than North American and European cohorts, with a similar clinical phenotype. Despite a 42% relapse rate, most patients showed meaningful improvement. These findings provide a regional benchmark for future prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.